Introduction
The mixed-lineage leukemia (MLL) gene, located on 11q23, is a mammalian homolog of the Drosophila melanogaster trithorax gene and serves as a component of the proteins associated with SET1 (COMPASS)-like complex.
1 COMPASS-like complexes methylate Lys4 on histone H3 (H3K4) through their conserved SET domain, and MLL associates with cofactors such as menin, a tumor suppressor, for chromatin localization and H3K4 trimethylation of genes including HOX genes. [2] [3] [4] In addition, MLL may regulate epigenetic inheritance by promoting transcriptional reactivation following mitotic chromosome condensation through a H3K4 trimethylationindependent mechanism. 5 In mouse development, Mll is necessary for establishment of definitive hematopoiesis and expansion of hematopoietic progenitors, whereas in adult hematopoiesis, it maintains hematopoietic stem cell (HSC) quiescence and promotes progenitor proliferation. [6] [7] [8] In Mll knockout mice, the defect in hematopoietic progenitor expansion is reversible on re-expression of Hox genes, demonstrating that Hox gene expression, as regulated by Mll, is critical in normal hematopoiesis.
MLL translocations are associated with pathogenesis of multiple types of leukemia, identified in up to 10% of de novo acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). 9, 10 In ALL, t(4;11) is the most frequent translocation, whereas t(9;11)(p21;q23) is most commonly associated with AML and myelodysplastic syndrome (MDS)/secondary leukemia, respectively. In MLL-rearranged leukemia, translocation of MLL with a variety of translocation partner genes, such as AF4, AF9, and ENL, results in the loss of the catalytic SET domain. Instead, the products of fusion partner genes confer the ability to recruit a histone methyltransferase, DOT1L, to target genes determined by specific recognition elements in the remaining portion of MLL.
11,12 DOT1L, when recruited to MLL target genes, aberrantly methylates genes such as HOXA9 and MEIS1, enhancing their expression. [13] [14] [15] [16] This may result in leukemogenesis, because ectopic expression of Hox genes such as Hoxb8, Hoxa7, and Hoxa9 have been shown to induce leukemia in mice, and t(7;11)(p15;p15) HOXA9-NUP98 fusion is associated with some human AML. [17] [18] [19] MLL rearrangement may also lead to leukemogenesis via deregulation of cell cycle and proliferation in myeloid or lymphoid lineages, through binding of rearranged MLL with c-Myc, and ATR and upregulation of the Wnt/b-catenin pathway. [20] [21] [22] ALL in infants is biologically distinct from ALL in older children, with 70% to 80% of infant cases associated with MLL translocations. 23 Although long-term event-free survival rates of ;80% are reported in older children with ALL, prognosis for infants is at ;40%, and prognosis for infants diagnosed with MLL-rearranged leukemia is significantly poorer than in MLL-nonrearranged cases. [23] [24] [25] In some malignancies such as adult AML, malignant stem cells may play important roles both in the initiation of disease and in disease relapse. The high failure rate in the treatment of infant MLL-rearranged leukemia is associated with disease relapse, suggesting that leukemiainitiating cell (LIC)-targeted therapy may improve patient outcomes. Unlike childhood B-cell lineage ALL in which CD34, CD10, and CD19 have been reported as potential markers for LICs, 26 MLLrearranged ALL is characterized by co-expression of B-cell and myeloid lineage antigens, suggesting that malignant transformation may have occurred in earlier stages of hematopoiesis. Characterizing MLL-rearranged ALL LICs and understanding the developmental origin and hierarchy in MLL ALL may lead to identification of mechanisms for disease relapse and development of effective therapeutic strategies.
Transplantation of murine or human HSCs/hematopoietic progenitor cells (HPCs) expressing MLL fusion proteins such as MLL-AF9 and MLL-ENL has provided highly informative in vivo models of MLL-rearranged leukemia. Although MLL-ENL-expressing murine HSCs/HPCs induce myeloid leukemia, MLL-ENL-expressing human lineage-negative cells induce lymphoid leukemia exclusively. 27, 28 In patients, MLL-ENL is associated more frequently in ALL than AML.
MLL-AF9-expressing human cord blood (CB) CD34
1 HSC/HPCs develop either myeloid or lymphoid leukemia in vivo depending on the expression of human cytokines in the mouse microenvironment.
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These studies illustrate the complexity of developmental hierarchy and lineage determination in MLL-rearranged leukemia.
In the present study, we identified phenotypically and functionally distinct populations of MLL-rearranged ALL LICs in MLL-AF4, MLL-AF9, and MLL-ENL patient samples in an in vivo xenotransplantation model. In addition, we demonstrated the presence of normal HSCenriched MLL translocation-negative population in MLL-rearranged ALL patient samples, which had the capacity to repopulate normal human hematopoiesis in vivo. Finally, we identified genes differentially expressed between MLL LICs and normal HSCs including cell surface molecules that may serve as therapeutic targets. Our data, through direct analysis of primary MLL-rearranged leukemia in vivo, give insights into hierarchy of leukemogenesis in infant MLL-rearranged leukemia and identify potential therapeutic targets in MLL LICs.
Materials and methods

Patient samples
Patient samples were collected with written informed consent from parents/ guardians of infant ALL patients in accordance with the Declaration of Helsinki and under approval of the Institutional Review Boards at each participating institution. All experiments were performed according to research protocol associated with the Japan Infant Leukemia Study Group protocol MLL96 and the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) protocol MLL-10 (UMIN Clinical Trials Registry number UMIN000004801; research protocol approval number 016). Samples were obtained fresh and mononuclear cells were isolated using densitygradient centrifugation before analysis and/or sorting. Normal CB and bone marrow (BM) mononuclear cells were purchased from Cambrex (Walkerville, MD). null [NSG] ) mice developed at the Jackson Laboratory were used for in vivo transplantation experiments. Mice were bred and maintained under defined flora at the animal facility of RIKEN and at The Jackson Laboratory according to guidelines established by the Institutional Animal Committees at each institution.
Flow cytometry and fluorescence-activated cell sorting
For flow cytometric analysis and fluorescence-activated cell sorting (FACS), patient-derived mononuclear cells and recipient BM, spleen, liver, testis, and peripheral blood (PB) cells were labeled with monoclonal antibodies as listed in supplemental Table 8 available on the Blood Web site. The purity of sorted cells was .98%.
Xenotransplantation
Newborn NSG mice received 150 cGy total body irradiation followed by intravenous injection of sorted cells. To evaluate in vivo leukemia initiating capacity, 10 2 to 10 5 sorted patient BM or PB cells were injected per recipient. The sorting strategy and phenotypes of transplanted cells for each transplantation experiment are described in Results and indicated in the figures.
Morphological analysis
Cytospin preparations were made using Shandon Cytospin 4 cytocentrifuge (Thermo Electric, Waltham, MA). May-Grunwald-Giemsa staining was performed using standard procedures. Light microscopy was performed using Zeiss Axiovert 200 (Carl Zeiss).
Fluorescence in situ hybridization
Cytospin specimens were fixed with methanol and glacial acid for 15 minutes on ice. After denaturation with 70% formamide and dehydration with 70% ethanol, the cells were stained with a probe detecting MLL fusion (LSI MLL Dual color Break Apart Rearrangement Probe; Abbott) at 37°C overnight. Nuclei were counterstained with 4,6 diamidino-2-phenylindole.
Histological studies
Tissues were fixed with 4% paraformaldehyde. Hematoxylin-eosin staining was performed using standard methods. Confocal microscopy was performed using Zeiss LSM710 (Carl Zeiss). Light microscopy was performed using Zeiss Axiovert 200 (Carl Zeiss).
B-cell clonality assay
DNA samples derived from MLL-rearranged infant ALL were subjected to B-cell clonality assay based on rearrangement patterns of immunoglobulin heavy chain (IGH) gene by using the IGH Gene Clonality Assay (Invivoscribe Technologies; Cat No. 1-101-0061). Polymerase chain reaction products were sized on an ABI 3130xl DNA sequencer (Life Technologies).
Gene expression profiling
To identify molecules expressed in MLL LICs, CD34
CD19
1 cells, and CD34 2 CD19 1 cells derived from 12 patients and normal HSC samples were subjected to microarray analysis. From 20 ng total RNA extracted from FACSpurified cells using TRIzol (Invitrogen), cDNA was amplified using Ovation RNA Amplification System V2 Kit (NuGEN). The amplified cDNA was fragmented and labeled for Human Genome U133 plus 2.0 GeneChip (Affymetrix) expression array analysis using the FL-Ovation cDNA Biotin Module V2 kit. Microarray data were analyzed using the Bioconductor package (http://www. bioconductor.org/). The signal intensities of the probe sets were normalized using the GeneChip Robust Multiarray Averaging (GC-RMA) program. 30 RankProd was used to select differentially expressed genes between LICs and HSCs with a cutoff P value of .01 and an estimated false-positive rate of 0.05. 31 Limma was used to selected differentially expressed genes among MLL-AF4, MLL-ENL, and MLL-AF9 with a cutoff P value of .01 and 1.5-fold change (log 2 ). 32 Gene annotation data were obtained from the RefDIC database. 33 
Statistical analysis
Numerical data are presented as means 6 standard error of the mean. The differences were examined using a 2-tailed t test (GraphPad Prism; GraphPad).
Accession numbers
Affymetrix gene expression data will be deposited in RefDIC database under the following accession numbers: RSM08287, RSM08288, RSM08289, RSM08292, RSM08293, RSM08294, RSM08295, RSM08395, RSM09150, RSM09151, RSM09152, RSM09189, RSM09190, RSM09536, RSM09537, RSM13162, RSM13489, RSM13490, and RSM13491.
Results
Distinct expression patterns of CD34 and CD38 in MLL-rearranged ALL We analyzed expression of CD34 and CD38 in samples obtained from infants with MLL-rearranged ALL associated with 3 distinct translocations: MLL-AF4 (n 5 14), MLL-AF9 (n 5 7), and MLL-ENL (n 5 7). Patient characteristics and frequency of cell populations as determined by surface expression of CD45, CD34, CD38, CD19, and CD33 are shown in Table 1 . Expression patterns of CD34 and CD38 varied depending on MLL fusion partner. In MLL-AF4 cases, we found both CD34 Figure 1A , lower). In contrast, in all MLL-AF9 cases, CD45 1 leukocytes were mostly CD34 2 cells (97.6 6 1.0%, n 5 7; case 14 shown as an example in Figure 1B ). Figure 1C Figure 2B ). Overall, we found CD34 Table 1 ; case 3 shown as an example in Figure 2C ). In the BM of secondary recipients engrafted with fraction 1, fraction 2, and fraction 4 (CD34
CD19
1 ALL cells were predominant (supplemental Table 1 ; case 3 shown as an example in Figure 2C ). In contrast, in the BM of the recipient of fraction 3 and fraction 5 (CD34
1 cells were generated, as well as CD34 Table 1 ; case 3 shown as an example in Figure 2C ). These findings indicate the presence of both CD34 CNS, central nervous system; LN, lymph node; n.a., frequency not available due to low frequency of parent population; WBC, white blood cell count; (2), absence of extramedullary disease;
1, presence of extramedullary disease.
an example in supplemental Figure 2 Table 2 ; case 14 shown as an example in supplemental Figure 2B , lower). In these recipients, the majority of human CD45 Figure 2D ). In cases 18 and 21, the major cell population is CD34 1 CD38
1
. In cases 19 and 20, the major population is CD34 negative. In all 4 cases, the major cell population (whether CD34
2 ) contained self-renewing LICs that initiate leukemia in primary and secondary recipients (supplemental Table 3 ; cases 18 and 20 shown as examples in Figure 2E ). BLOOD Figure 3B ; supplemental Table 4 ). In the spleen, 51.7 6 5.5% of CD19 1 B-lineage cells were Figure 3E ). In addition, MLL-AF9 CD34 
CD33
2 cells is summarized in Figure 3H . These findings indicate that CD34
2 cells in infant MLL-AF4, -AF9, and -ENL ALL are highly enriched for normal hematopoietic stem/progenitor cells.
IGH rearrangements in infant MLL ALL LICs
We proceeded to determine whether dominant leukemia clones existed in patients and recipient mice by examining IGH rearrangement. VDJ and DJ rearrangements were identified in CD34 Table 5 ; shared peaks at 270, 134, and 411 bp using primer set B, C, and D-2 in case 3 shown as examples in Figure 4A ). In addition, there were dominant clones present among MLL-AF4 patients as evidence by shared IGH rearrangement peaks (indicated in blue in supplemental Table 5 ). MLL-AF4 patient CD34
CD33
2 cells, which were found to contain the MLL rearrangement, also showed clonal bands (supplemental Table 5 Table 5 ). Additional IGH rearrangements were also detected in the recipients (supplemental Table 5 ). Shared IGH clones were also detected in CD34 Table 5 ; case 3 shown as an example in Figure 4B ). In a recipient engrafted with CD34 patients or between patients and recipients (supplemental Table 5 ; case 17 shown as an example in supplemental Figure 5 ). In contrast, human CD19 1 B cells in recipients of CD34 Table 5 ) showed polyclonal IGH rearrangement patterns comparable to those of human B cells in normal CB HSC recipients (CB HSC-engrafted recipient-1/2 in supplemental Table 5 ) that exhibit physiological diversity of IGH rearrangements (case 3 shown as an example in Figure 4B ).
Gene expression signatures in MLL LICs and HSCs
We performed global transcriptome analyses of LICs from MLLrearranged infant ALL patient samples (supplemental Figure 6) . First, genes specifically up-and downregulated in LICs isolated from MLL-AF4, MLL-AF9, and MLL-ENL patient samples were identified through 3-way comparison (supplemental Figure 6A ; supplemental Table 6 ). Genes differentially expressed in MLL-AF4 LICs compared with MLL-AF9 and MLL-ENL LICs included HOXA clusters (downregulated) and TET2 and DR1 (upregulated). TET2 encodes a methylcytosine dioxygenase, a member of the Ten-ElevenTranslocation (TET) family of proteins, which mediates the process of active DNA demethylation. [35] [36] [37] Loss-of-function mutation in TET2 is frequently found in adult AML and is associated with adverse prognosis. [38] [39] [40] DR1 encodes a transcriptional repressor of TATA boxbinding protein (TBP) promoter complexes. TBP-related factors are required for normal early development and hematopoiesis. For personal use only. on November 13, 2017 . by guest www.bloodjournal.org From ZNF521 was among the genes upregulated in MLL-AF9 LICs compared with MLL-AF4 and MLL-ENL LICs. ZNF521 encodes a zinc finger protein that inhibits early B-cell factor 1 (EBF1) which is required for normal B-cell development and differentiation. In Ebf1 knockout mice, accumulation of early lymphoid progenitors that lack B-lineage priming but have T-and myeloid lineage potential occurs while mature B cells are completely absent. 42, 43 Mice transgenic for Zfp521, a murine homolog for ZNF521, were also reported to develop B-lineage ALL. 44 Genes upregulated in MLL-ENL LICs compared with MLL-AF4 and MLL-AF9 LICs included SIRPA and SATB1. SIRPA encodes an Ig superfamily inhibitory immunoreceptor, signal regulatory protein-a (SIRPa), expressed on macrophages, dendritic cells, and neurons. [45] [46] [47] [48] SIRPa binding with its ligand CD47 results in decreased phagocytosis by macrophages. 49 SIRPa-CD47 interaction may be one of the mechanisms by which malignant cells evade innate immune responses, as suggested by reports that CD47 blocking antibodies result in elimination of tumor cells in various models of human leukemia and solid tumors. [50] [51] [52] [53] [54] SATB1 encodes a matrix protein that recruits chromatin-remodeling factors by binding nuclear matrix and scaffold-associating DNAs, thereby regulating chromatin structure and gene expression. Special AT-rich sequence-binding protein 1 (SATB1) expression is associated with multiple solid tumors including colorectal cancer, breast cancer, malignant melanoma, gastric cancer, bladder cancer, and prostate cancer. SATB1 is also involved in normal T cell immunity. It is known to inhibit the expression of Forkhead box P3 transcription factor (FoxP3), a key determinant of normal regulatory T-cell development and function, and is required for Th2 cytokine expression. 55, 56 Some of the genes were commonly upregulated in our study and in previously reported MLL translocation-specific gene expression signatures (supplemental Figure 6B) . 57 Next, we compared gene expression profiles of CD34 Figure 6D ). CCND2 (cyclin D2) and BAALC expression have prognostic relevance in leukemia and other malignancies. 58, 59 In addition, we compared gene expression profiles of 5 MLL-AF4 cases, 4 MLL-AF9 cases, and 3 MLL-ENL cases with those of normal human BM CD34 1 CD38 2 HSCs isolated from 3 healthy donors. We found relative overexpression of cell surface molecules CD9, CD24, CD32, CD127, and CD180b in MLL-AF4 CD34 Figure 5A ). We validated the expression of these molecules in MLL-ALL LICs (4 cases of MLL-AF4, 6 cases of MLL-AF9, and 4 cases of MLL-ENL) and in normal human CB mononuclear cells (MNCs; n 5 3) by flow cytometry ( Figure 5B ; supplemental Table 7 ). In MLL-AF4, CD9 and CD32 were highly expressed in CD34 
CD33
2 population did not ( Figure 5C ). In MLL-AF9 cases 16 and 17, CD9 and CD24, and CD32 and CD180, respectively, were highly expressed by CD34 Figure 5C ). In MLL-AF9 case 14, CD24
was differentially expressed between HSC/HPC and LIC populations (supplemental Figure 7A) (supplemental Figure 7B ).
Discussion
Despite significant improvement in overall clinical outcomes of pediatric ALL in the last few decades, the prognosis in MLLrearranged ALL has remained poor. To understand the pathogenesis of this disease entity and to develop effective therapeutic strategies, mouse syngeneic and xenogeneic transplantation of MLL-AF9-or -ENL-expressing mouse or human BM cells have been developed. These systems have provided important insights into the pathogenesis of MLL-rearranged ALL and have led to identification of potential therapeutic targets (eg, Rac signaling or DOT1L). In addition, direct evaluation of primary patient cells in vivo may also facilitate translation of research findings into medicine. In the present study, we examined the biology of primary LICs in infant MLL-rearranged ALL using the newborn NSG xenogeneic transplantation system. The NSG xenogeneic transplantation system supports long-term engraftment and multilineage differentiation of normal HSCs. 60, 61 The NSG xenograft system also allows the identification of LICs and the analysis of engrafted human leukemia cells in vivo. 62 In samples obtained from infants with MLL ALL, we identified LICs with distinct surface expression patterns of CD34, CD38, CD19, and CD33 according to fusion partners. Our findings do not suggest large differences in LIC frequency among leukemia-initiating populations in MLL-ALL patient samples examined, although formal limiting dilution transplantation experiments are required to determine LIC frequencies rigorously.
MLL leukemia is characterized by surface expression of B-cell antigens (eg, CD19), as well as myeloid cell antigens (eg, CD33, CD15, and CD13). Although CD19 expression is considered an important marker for B-ALL initiating cells, 63 B-ALL initiation by CD19-negative cells was confirmed in NOD/SCID repopulating assay in several reports. 26, 64 In this study, we found no significant difference in leukemia-initiating capacity between CD34 To determine potential therapeutic targets in infant MLL-ALL, we examined gene expression profiles in primary MLL ALL LICs. We found differential expression of some genes or groups of genes according to type of MLL translocation (eg, HOXA clusters and related genes) and phenotype of LICs (eg, DNTT, CCND2, and BAALC), but we also found patient-specific differences in LIC signature. By comparing expression profiles of primary MLL ALL LICs with those of HSCs, we identified CD9, CD32, and CD24 as cell surface molecules that more specifically mark LICs and not HSCs. Of note, CD32 shows higher levels of expression compared with CD9, CD24, or CD180 in CB-derived CD34 65 By using agents that target surface molecules with selective expression in LICs compared with HSCs, it may be possible to minimize treatment-related hematopoietic adverse effects only targeting mature hematopoietic subsets such as normal human B cells. Knockout mice for these molecules have not shown serious defects in hematopoiesis, giving some support to the speculation. [66] [67] [68] CD9, CD32, and CD24 are reported to be expressed by non-MLL-rearranged hematologic malignancies and solid tumors. 65, [69] [70] [71] Targeting CD24 with antibody resulted in the significant reduction of immortalized lung tumor cells in a xenograft model. 72 Recent studies have reported significantly improved outcomes in B-lymphoid malignancies by use of antibody drug and chimeric-antigen receptor T cells (CART). 73, 74 Development of new therapeutic agents targeting molecules identified in the present study using CART technology may prove beneficial to MLL-rearranged ALL, the majority which are infants. Therapeutic strategies that combine antibody drug/CART with drugs that target key molecules in MLLinduced leukemogenesis may provide us with a better chance for improved outcomes in patients with MLL-rearranged ALL. Whether LIC-specific surface markers identified are suitable for such use awaits further study.
